Lucy Scientific Discovery is partnering with non-profit organization that advocates for legal access to psilocybin therapy for Canadians, TheraPsil, to advance medical access and research.
Advocating for compassionate access since 2019, TheraPsil supports patients with their applications for ministerial approval of psilocybin for medical purposes. It also connects approved patients with qualified practitioners to receive the therapy treatment.
Building upon TheraPsil’s visionary initiative, Project Solace – a medical data and access project aiming to inform the development of regulated psilocybin therapy being carried out in collaboration with UK reform group Drug Science – the partnership aims to provide compassionate care while collecting real-world data to support the effectiveness and safety of the therapy.
The partnership will enable Lucy to introduce a suite of natural psilocybin products into the Canadian market, allowing the company to gain valuable early consumer feedback and build brand recognition in Canada.
Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., stated: “We are thrilled to collaborate with TheraPsil, as it provides us with a unique opportunity to bring natural psilocybin products to market in Canada.
“By leveraging TheraPsil’s expertise and our shared commitment to patient well-being, we aim to gain valuable insights, build brand recognition, and positively impact the lives of individuals seeking alternative therapies.”
“Canadians are in urgent need of compassionate access to psilocybin,” said TheraPsil CEO Spencer Hawkswell.
“Having Lucy join the project is going to help thousands of patients connect with doctors and therapists who will be able to support their SAP exemptions to help them access psilocybin. We’re excited to work with Lucy Scientific and applaud their support of patients seeking access to psilocybin.”
Lucy Scientific Discovery has stated that it expects that by combining these resources, knowledge and industry leadership of Lucy Scientific Discovery Inc. and TheraPsil, the collaboration is poised to make significant contributions to the field of psychedelic medicine.
